<DOC>
	<DOCNO>NCT00891384</DOCNO>
	<brief_summary>This trial randomise , parallel-group , multicenter phase III study maintenance therapy lenalidomide patient multiple myeloma treat high-dose therapy autologous stem cell transplantation first line therapy .</brief_summary>
	<brief_title>Comparison 25mg Versus 5 mg Lenalidomide Maintenance Therapy Patients With Multiple Myeloma</brief_title>
	<detailed_description>High-dose therapy perform first line treatment . After high-dose therapy autologous stem cell transplantation patient include randomise . Three month high-dose therapy patient receive consolidation therapy 6 cycle lenalidomide 25 mg daily 21 day every 28 day . Afterwards patient receive maintenance therapy accord assign treatment arm . Randomisation perform 1:1 ratio continuous maintenance therapy either 25mg 5mg lenalidomide daily 21 day every 28 days.Randomisation stratify ISS-stage ( 1+2 v 3 , age ( young 66 year versus 66 year old ) , response high-dose therapy ( CR+vgPR vs PR v MR/SD . Patients treated disease progression .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Signed informed consent form Age 1875 year Able adhere study visit schedule protocol requirement Patients multiple myeloma receive highdose therapy autologous stem cell transplantation firstline therapy within last 90 120 day show progressive disease afterwards . Patients may receive 6 cycle prior induction therapy 2 cycle prior mobilisation chemotherapy . A bortezomib thalidomide induction therapy allow . Patients may also receive prior radiation therapy Measurable level myeloma paraprotein serum ( &gt; 0.5 g/dL ) urine ( &gt; 0.2 g/24hours ) measurable free light chain ( FLC ) serum ( &gt; 50 mg/l ) abnormal FLC ratio must document time first diagnosis . ECOG performance status = 2 study entry Laboratory functional test result within range : ANC ≥ 1,000/μL Platelet count ≥ 100,000/μL Total bilirubin 2.5 mg/dL AST ( SGOT ) ALT ( SGPT ) 3 x ULN Patients impair renal function include The patient must able adhere pregnancy precaution Disease free prior malignancy 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Pregnant breast feeding females Any condition laboratory abnormality place subject unacceptable risk he/she participate study confounds ability interpret data study Known allergic/hypersensitivity reaction thalidomide , lenalidomide component treatment Any cutaneous grade ≥ 3 adverse reaction ( example desquamate rash ) take thalidomide similar drug Any prior use lenalidomide Known positive HIV active infectious hepatitis , type A , B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>lenalidomide</keyword>
</DOC>